Keywords: Aduro BioTech, BioSante, GVAX assets, Immunology portfolio, Aspen Pharmacare, Merck & Co, API facility, Netherlands

Aduro BioTech buys all GVAX assets from BioSante; Aspen in talks to buy Merck unit

Article | 05 February 2013

Print This

Aduro BioTech, a privately-held, US venture capital backed biotechnology company, says it has acquired all GVAX assets from US drug ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in